1. Home
  2. XPER vs MGNX Comparison

XPER vs MGNX Comparison

Compare XPER & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xperi Inc.

XPER

Xperi Inc.

N/A

Current Price

$5.42

Market Cap

271.2M

Sector

Technology

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$1.99

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XPER
MGNX
Founded
1990
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.2M
262.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
XPER
MGNX
Price
$5.42
$1.99
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
★ $11.40
$8.00
AVG Volume (30 Days)
394.7K
★ 1.0M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $448,105,000.00
$149,500,000.00
Revenue This Year
$1.90
N/A
Revenue Next Year
$4.49
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.91
$1.32
52 Week High
$8.75
$5.08

Technical Indicators

Market Signals
Indicator
XPER
MGNX
Relative Strength Index (RSI) 44.52 25.46
Support Level $4.99 $1.63
Resistance Level $5.92 $3.39
Average True Range (ATR) 0.26 0.18
MACD -0.00 0.00
Stochastic Oscillator 27.86 0.00

Price Performance

Historical Comparison
XPER
MGNX

About XPER Xperi Inc.

Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: